Table 2.

Univariate and multivariate analysis of factors associated with overall survival

Parameter	Univariate analysis		Multivariate analysis
			Model 1a		Model 2b
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
IL6 (> 6.53 pg/mL)	2.4 (1.5–3.88)	< 0.001	2.35 (1.35–4.1)	0.002	2.2 (1.28–3.8)	0.005
IL8 (> 60.8 pg/mL)	1.8 (1.1–2.9)	0.011	1.32 (0.77–2.3)	0.305	1.2(0.71–2.0)	0.481
Sex (Male vs. Female)	0.59 (0.23–1.5)	0.26
Age (≥ 65 vs. < 65 years)	0.8 (0.5–1.3)	0.36
ECOG (1 vs. 0)	0.96 (0.57–1.6)	0.87
Cirrhosis (Yes vs. No)	2.4 (1.1–5.2)	0.032	2.33 (0.94–5.81)	0.069	2.4 (0.99–6.1)	0.053
Hepatitis B Etiology (Yes vs. No)	1.5 (0.53–4)	0.47
Hepatitis C Etiology (Yes vs. No)	1.3 (0.73–2.2)	0.39
Alcohol Etiology (Yes vs. No)	1.2 (0.78–2)	0.36
Previous TACE (Yes vs. No)	0.87 (0.5–1.5)	0.63
PVI (Yes vs. No)	1.3 (0.81–2.1)	0.28
Child–Pugh (B vs. A)	3.3 (1.3–8.5)	0.014	2.91 (0.98–8.64)	0.055	2.7 (0.98–7.3)	0.054
BCLC (C vs. B)	1.1 (0.53–2.3)	0.78
Albumin (< 36 g/L)	1.9 (1.1–3.3)	0.024	0.68 (0.33–1.43)	0.31	–	–
Total bilirubin (≥ 17 µmol/L)	2 (1.2–3.2)	0.009	1.71 (0.95–3.09)	0.073	–	–
AFP (≥ 400 vs < 400 ng/mL)	0.86 (0.53–1.4)	0.53
Diffuse disease (≥ 10 lesions)	0.77 (0.48–1.2)	0.28
Extrahepatic disease	0.96 (0.57–1.6)	0.89
mALBI grade (2b and 3 vs. 1 and 2a)	2.1 (1.2–3.6)	0.007	–	–	1.13 (0.62–2.07)	0.694

Bold type indicates statistical significance;

IL, interleukin; ECOG, Eastern Cooperative Oncology Group; TACE, transarterial chemoembolization; PVI, Portal vein invasion; BCLC, Barcelona Clinic Liver Cancer; AFP, alfa fetoprotein; mALBI, modified albumin–bilirubin

^aModel 1 was identified using Cox regression with albumin and total bilirubin, excluding mALBI grade

^bModel 2 was identified using Cox regression with mALBI grade as a composite factor, excluding albumin and total bilirubin